{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:42:25Z","timestamp":1783611745340,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T00:00:00Z","timestamp":1607990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jfma.2020.12.015","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T21:18:31Z","timestamp":1610140711000},"page":"2023-2031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan"],"prefix":"10.1016","volume":"120","author":[{"given":"Kun-Huei","family":"Yeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsai-Sheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Chi","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Tzu-Liang Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Hwa","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Wei","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Wen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Che","family":"Kuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Fan","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Wei","family":"Duann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Shiuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Ting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Fiala-Buskies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaw-Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jfma.2020.12.015_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.jfma.2020.12.015_bib2","series-title":"Surgical treatment of colorectal cancer: asian perspectives on optimization and standardization [internet]","first-page":"3","article-title":"Epidemiology of colorectal cancer in asia-pacific region","author":"Park","year":"2018"},{"key":"10.1016\/j.jfma.2020.12.015_bib3","author":"Taiwan Ministry of Health and Welfare"},{"issue":"6","key":"10.1016\/j.jfma.2020.12.015_bib4","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/ijc.28669","article-title":"Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer","volume":"135","author":"Schmieder","year":"2014","journal-title":"Int J Cancer"},{"issue":"9863","key":"10.1016\/j.jfma.2020.12.015_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jfma.2020.12.015_bib7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdx738","article-title":"Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS","volume":"29","author":"Yoshino","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jfma.2020.12.015_bib8","first-page":"185","article-title":"Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy: results of the large, single-arm, open-label phase IIIb CONSIGN study","volume":"24","author":"Van Cutsem","year":"2019","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.jfma.2020.12.015_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(09)70160-3","article-title":"Population-based differences in treatment outcome following anticancer drug therapies","volume":"11","author":"Ma","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.jfma.2020.12.015_bib10","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1007\/s10637-014-0154-x","article-title":"Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations","volume":"33","author":"Yoshino","year":"2015","journal-title":"Invest New Drugs"},{"issue":"6","key":"10.1016\/j.jfma.2020.12.015_bib11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jfma.2020.12.015_bib12","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s12885-016-2440-9","article-title":"Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program","volume":"16","author":"Adenis","year":"2016","journal-title":"BMC Canc"},{"issue":"7","key":"10.1016\/j.jfma.2020.12.015_bib13","first-page":"e450","article-title":"Large-scale, prospective observational study of regorafenib in Japanese patients with metastatic colorectal cancer in a real-world clinical setting","volume":"24","author":"Yamaguchi","year":"2019","journal-title":"Oncology"},{"issue":"4_suppl","key":"10.1016\/j.jfma.2020.12.015_bib14","article-title":"Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: final results of the prospective multicentre non-interventional RECORA study","volume":"36","author":"Schulz","year":"2018","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.jfma.2020.12.015_bib15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejca.2019.09.015","article-title":"Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study","volume":"123","author":"Ducreux","year":"2019","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.jfma.2020.12.015_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.jfma.2020.12.015_bib17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11523-014-0352-7","article-title":"Regorafenib: start low and go slow","volume":"10","author":"Tabchi","year":"2015","journal-title":"Target Oncol"},{"issue":"8","key":"10.1016\/j.jfma.2020.12.015_bib18","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(19)30272-4","article-title":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study","volume":"20","author":"Bekaii-Saab","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4_suppl","key":"10.1016\/j.jfma.2020.12.015_bib19","article-title":"Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer that progressed after standard chemotherapy","volume":"36","author":"Kudo","year":"2018","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.jfma.2020.12.015_bib20","author":"Clinicaltrials gov"},{"issue":"12","key":"10.1016\/j.jfma.2020.12.015_bib21","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1159\/000356814","article-title":"RAS, BRAF, and TP53 gene mutations in Taiwanese colorectal cancer patients","volume":"36","author":"Chang","year":"2013","journal-title":"Onkologie"},{"key":"10.1016\/j.jfma.2020.12.015_bib22","doi-asserted-by":"crossref","first-page":"18678","DOI":"10.1038\/srep18678","article-title":"Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.jfma.2020.12.015_bib23","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/jjco\/hyt054","article-title":"Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial","volume":"43","author":"Ueda","year":"2013","journal-title":"Jpn J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jfma.2020.12.015_bib24","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/annonc\/mdv244","article-title":"Regorafenib-associated hand\u2013foot skin reaction: practical advice on diagnosis, prevention, and management","volume":"26","author":"McLellan","year":"2015","journal-title":"Ann Oncol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092966462030615X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092966462030615X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:45:34Z","timestamp":1760539534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092966462030615X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S092966462030615X"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2020.12.015","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2020.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}